Genetic Technologies Limited (ASX:GTG)

Market Cap	5.67M -75.4%
Revenue (ttm)	9.17M +46.0%
Net Income	-9.68M
EPS	-0.07
Shares Out	145.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,071
Average Volume	60,409
Open	0.0390
Previous Close	0.0390
Day's Range	0.0390 - 0.0390
52-Week Range	0.0360 - 0.3000
Beta	0.18
RSI	45.44
Earnings Date	Jul 29, 2026

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health c...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1987
• Employees: 55
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GTG

Financial Performance

In fiscal year 2024, Genetic Technologies's revenue was 9.67 million, a decrease of -6.52% compared to the previous year's 10.35 million. Losses were -12.02 million, 2.27% more than in 2023.